: iStockAnalyst.com Symbols Feed

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

Trends Shaping The Health Care Industry: Part 2

Sat, 06 Jun 2009 18:09:00 GMT

If you have not read part one of this three part article, please find the link here. As I have already highlighted, the health care industry is subject to many swings that are caused by macroeconomic variables, regulation, trends, and beliefs. These changes can be hard to pick up on, especially if you are new to the health care industry or if you are not as familiar with it as with more experienced investors. In the first part of this article, I explained how the Obama Administration and the FDA are shaping the environment for health care companies. It is very important to understand the relationship between companies and their stakeholders and the major forces in the[More...]

Biotech Industry - Industry Outlook

Thu, 16 Apr 2009 20:54:01 GMT

Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See[More...]

How To Play The Healthcare Sector

Mon, 30 Mar 2009 13:34:00 GMT

The recent volatility from the Healthcare sector has left many investors weary about where to place their money. General market swings aside, M&A activity and legislative developments have intensified the uncertainty in the sector, but have also lead to many investment opportunities. M&A has been very exciting and has ramped up heavily in the last few months. Pfizer(PFE: 14.04, 0.00 [More...]

Biotech Stocks: The One Sector Outperforming The S&P 500

Tue, 24 Mar 2009 13:41:00 GMT

Biotech Stocks: The One Sector Outperforming The S&P 500 by Marc Lichtenfeld, Senior Analyst, Smart Profits Report Editor’s Note: With so many biotech stocks making big moves and pharmaceutical merger activity moving faster than anything else right now, we turned to one of the smartest analysts in the lucrative biotech field to give us his take on what we should be doing… When I was in my early 20s, I had one friend who was always on the prowl for Mrs. Right (or at least Mrs. Right Now) whenever we went out. The[More...]

Weekly Review: (03-09-2009 to 03-13-2009)

Sun, 15 Mar 2009 16:38:56 GMT

US stocks finished with strong weekly gains as investors snapped up shares of banks after chief executives of Citigroup, JP Morgan and Bank of America said that their banks were profitable in January and February.[More...]

Roche Keeps M&A Party Rolling With $46.8 Billion Deal For Genentech

Fri, 13 Mar 2009 14:34:00 GMT

By Don Miller Associate Editor Money Morning Big Pharma’s rapidly accelerating consolidation pattern snowballed yesterday (Thursday) as Roche Holding AG (ADR: RHHBY) struck a deal to... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

The Biotech Sector: Big Mergers Could Mean Big Gains For Biotechnology

Thu, 12 Mar 2009 22:38:00 GMT

Normal 0 by Marc Lichtenfeld, Senior Analyst, Smart Profits Report Thursday, March 12, 2009 Talk about a winter of discontent… Over the past seven weeks, we’ve seen quite possibly one of the best examples of stock market fear in history. Actually, it’s not fear. It’s pure irrationality, as top-quality stocks have been spanked down to bargain-basement levels, despite no discernable change in their businesses. But business is still booming in the biotech sector… Over that time,[More...]

Wall Street Rallies Despite GE Downgrade, Bank Of America Soars

Thu, 12 Mar 2009 22:17:47 GMT

US stocks rallied on Thursday after General Electric assured that ratings cut would not have any "significant operational or funding impacts." Shares also climbed after Bank of America CEO Ken Lewis said that the bank was profitable in the months of.....[More...]

What The Pundits Are Saying About Gilead and CV Therapeutics

Thu, 12 Mar 2009 21:35:00 GMT

“Another deal believe it or not in the drug industry has just come down. This time Gilead Sciences is buying CV Therapeutics, a $1.4 billion deal. We’ve seen so many acquisitions including Genentech-Roche which we talked about happening in recent days. $1.4 billion for CV Therapeutics which works out to $20 a share in cash.” (Fox Business Network, 8:23AM) “Gilead buying CV Therapeutics, a big week for healthcare related stocks. $100 to $150 billion in healthcare deals in the past few months. Outrageous!…We’re talking about news that Gilead Sciences is going to buy CV Therapeutics in cash for $20 a share, about $1.4 billion topping a recent bid for the company. CV is a small cardiovascular drug maker and shares are shooting up.” (Fox Business Network, 9:27AM) “Take a look at another deal out of the pharma space. Seems like that’s all we’ve been[More...]

Stocks Jump Despite GE Downgrade

Fri, 13 Mar 2009 14:46:00 GMT

U.S. stocks closed higher for a third straight session Thursday, with the Dow Jones industrial average moving back above the 7,000 level.
The market was led by gains in General Electric (GE) and General Motors (GM).
On Thursday, the 30-stock Dow Jones industrial average finished higher by 239.66 points, or 3.46%, at 7,170.06.

: iStockAnalyst.com Symbols Feed

Spotlight On: Biotech

Trends Shaping The Health Care Industry: Part 2

Biotech Industry - Industry Outlook

How To Play The Healthcare Sector

Biotech Stocks: The One Sector Outperforming The S&P 500

Weekly Review: (03-09-2009 to 03-13-2009)

Roche Keeps M&A Party Rolling With $46.8 Billion Deal For Genentech

The Biotech Sector: Big Mergers Could Mean Big Gains For Biotechnology

Wall Street Rallies Despite GE Downgrade, Bank Of America Soars

What The Pundits Are Saying About Gilead and CV Therapeutics

Stocks Jump Despite GE Downgrade

Big Deals to Reshape Bay Area Biotech

Wall Street rebounds after GE rating cut

Big Deals Reshape Bay Area Biotech Industry

Gilead to Acquire CV Therapeutics

CV Therapeutics Advises Stockholders on Astellas Offer

Astellas Hints at Launching Hostile Takeover Bid for CV Therapeutics

CV Therapeutics Reports $98.5 Million Loss

CV Therapeutics Rejects Astellas Proposal

Gilead Sciences Completes Acquisition of CV Therapeutics

AnalystChoice.Com Free Investment Opinion on PPDI, MEDX, CVTX and OSIP

Zacks Analyst Blog Highlights: Analog Devices Inc., Gilead Sciences, CV Therapeutics, Koninklijke Philips Electronics N.V., And Skyworks Solutions, Inc.

CV Therapeutics' Board of Directors Recommends Stockholders Accept Gilead Sciences' $20.00 per Share Cash Tender Offer

Run of 100% Profitable Stock Alerts Marches on for BullTrade

CV Therapeutics Announces Presentations at the American College of Cardiology 58th Annual Scientific Session

Astellas to Terminate Offer for CV Therapeutics - Mar 16 2009 3:19AM

Zacks Analyst Blog Highlights: Gilead Sciences, CV Therapeutics, The Boeing Co, Northrop Grumman Corp and eBay Inc.

Zacks Industry Outlook Highlights: Roche, Genentech, Gilead Sciences and CV Therapeutics

CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer

Form 4/A LANGE LOUIS G For: Apr 27 (10K)

Form 4 SUVARI TRICIA BORGA For: Apr 14 (10K)

Form 4 BLACKBURN BRENT K For: Apr 14 (10K)

Form 4 SPIEGELMAN DANIEL K For: Apr 16 (10K)

Form 4 STUART LEWIS J For: Apr 16 (10K)

Form 4 LANGE LOUIS G For: Apr 16 (10K)

Form 4 SHENK THOMAS E For: Apr 14 (10K)

Form 4 LEE KENNETH B JR For: Apr 14 (10K)

Form 4 GUTSHALL THOMAS L For: Apr 14 (10K)

Form 4 DAVIE JOSEPH MD PHD For: Apr 14 (10K)